Daiichi Sankyo

  • Rigel and Daiichi-Sankyo are collaborating to discover and develop inhibitors of a specific MDM2 inhibitor involved in cancer.

  • Rigel received two milestone payments from Daiichi-Sankyo for the successful delivery of two potent and selective inhibitors of MDM2.

  • Rigel may be eligible to receive additional milestone payments and also entitled to receive royalties on products emerging from this collaboration.

  • Daiichi Sankyo is conducting Phase 1 clinical trials with the lead oncology molecule in the collaboration.